CrushSCI.com
220Average days
208Median days
54Fastest days
567Longest days
9872025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

115 days

Psychosocial Well‐Being in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation and Their Caregivers: A Prospective Study

Authors
E. Cavagna; A. Leoni; E. Morello; G. Benedini; G. Brambilla; M. A. Abrami; D. Avenoso; G. Magliano; S. Bernardi; M. Farina; V. Radici; D. Russo; M. MalagolaShow moreShow less
Affiliations
1. Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science University of Brescia, ASST Spedali Civili di Brescia Brescia Italy; 2. ASST Spedali Civili di Brescia S.S.D. Psicologia Clinica Brescia Lombardy Italy; 3. Istituto di Medicina Molecolare “Angelo Nocivelli” ASST Spedali Civili di Brescia Brescia ItalyShow moreShow less
Source PDF DOI Publisher page
340 days

Geriatric Nutritional Risk Index Is Associated With Short‐ and Long‐Term Mortality in ICU Patients With Cancer: A Retrospective Study Based on MIMIC ‐ IV and eICU ‐ CRD Databases

Authors
Zhikun Xu; Yichun Jiang; Jiayang Huang; Qinhua Yang; Yijing Su; Dongting Peng; Boru Wu; Zhiming Chen; Xueyan LiuShow moreShow less
Affiliations
1. Department of Critical Care Medicine Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University) Shenzhen China; 2. Department of Pharmacy Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University) Shenzhen China; 3. Department of Gastroenterology Shenzhen Luohu People's Hospital, The Third Affiliated Hospital of Shenzhen University Shenzhen China; 4. Department of Anesthesiology Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University) Shenzhen ChinaShow moreShow less
Source PDF DOI Publisher page
227 days

Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, HER2 ‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates

Authors
Hiroko Shimada; Maki Todo; Hiroshi Ishiguro; Emi Mikami; Wakako Inohana; Taeko Kurosawa; Ayako Nakame; Ayaka Sakakibara; Yuki Ichinose; Akihiro Fujimoto; Asami Nukui; Aya Asano; Hideki Yokogawa; Masahiro Ohara; Kazuo Matsuura; Takahiro Hasebe; Nobuko Fujiuchi; Akihiko Osaki; Toshiaki SaekiShow moreShow less
Affiliations
1. Department of Breast Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan; 2. Department of Pharmacy Saitama Medical University Saitama International Medical Center Hidaka Saitama Japan; 3. Department of Breast Oncology Saitama Medical University Hospital Moroyama‐machi, Iruma‐gun Saitama JapanShow moreShow less
Source PDF DOI Publisher page
162 days

Lifetime Hormonal Exposure and Risk of Lung Cancer in Women: Results From a French Population‐Based Case–Control Study (The WELCA Study)

Authors
Youssouf Gueye; Emilie Cordina Duverger; Pascal Guénel; Marie Wislez; Jean Trédaniel; Hélène Blons; Pierre Laurent‐Puig; Martine Antoine; Mireille Matrat; Loredana Radoï; Marianne Canonico; WELCA study groupShow moreShow less
Affiliations
1. UVSQ, Inserm, Gustave Roussy, Equipe Exposome Hérédité Cancer et Santé, CESP, Université Paris‐Saclay Villejuif France; 2. Service d'Oncologie Thoracique Hôpital Cochin, Institut du Cancer Paris Carpem, Assistance Publique Hôpitaux de Paris (AP‐HP Centre), Centre de Recherche des Cordeliers, UMRS 1138 Complement, Inflammation and Cancers, Université Paris Cité Paris France; 3. Groupe Hospitalier Paris Saint Joseph, Université Paris Cité Paris France; 4. Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université Paris Cité Paris France; 5. Département de Médecine Génomique des Tumeurs et Cancers Assistance Publique Hôpitaux de Paris (AP‐HP Centre), Institut du Cancer Paris Carpem, Université Paris Cité Paris France; 6. Département de Pathologie Assistance Publique Hôpitaux de Paris (AP‐HP Centre), Hôpital Tenon Paris France; 7. Université Paris‐Est Créteil, UFR de Santé Créteil France; 8. Centre Hospitalier Intercommunal, Service des Pathologies Professionnelles et de l'Environnement Créteil France; 9. Faculté d'Odontologie Université Paris Cité Paris France; 10. Assistance Publique Hôpitaux de Paris (AP‐HP Nord) Colombes France; 11. UVSQ, Inserm, Equipe Epidémiologie Clinique et Pharmacoépidémiologie, CESP, Université Paris‐Saclay Villejuif FranceShow moreShow less
Source PDF DOI Publisher page
60 days

Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort

Authors
Xin Qi; Hewei Wang; Huan Zhang; Xueying Ren; Mingwei Ma; Xiaoying Li; Wanqi Zhang; Zhisong He; Yi Song; Cheng Shen; Wei Yu; Yu Fan; Xianshu Gao; Hongzhen LiShow moreShow less
Affiliations
1. Department of Radiation Oncology Peking University First Hospital Beijing China; 2. Department of Urology Peking University First Hospital Beijing ChinaShow moreShow less
Source PDF DOI Publisher page
160 days

Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High‐Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial

Authors
Nadia Linxi Feng; John Doering; Tzu‐Fei Wang; Ranjeeta Mallick; Grégoire Le Gal; Joseph Shaw; Danny Hill; Sudeep Shivakumar; Vicky Tagalakis; Phil Wells; Marc CarrierShow moreShow less
Affiliations
1. Faculty of Medicine McGill University Montreal Quebec Canada; 2. Department of Medicine University of British Columbia Vancouver British Columbia Canada; 3. Department of Medicine University of Ottawa at the Ottawa Hospital Ottawa Ontario Canada; 4. Method Center The Ottawa Hospital Research Institute Ottawa Ontario Canada; 5. Department of Medicine Sault Area Hospital Sault Ste. Marie Ontario Canada; 6. Department of Medicine Nova Scotia Health, Dalhousie University Halifax Nova Scotia Canada; 7. Jewish General Hospital, Lady Davis Institute for Medical Research McGill University Montreal Quebec CanadaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Cancer Medicine take to review a manuscript?

As of 2026-11-17, CrushSCI has 30 complete review records for Cancer Medicine. The fastest paper went from submission to acceptance in 54 days (Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis, received 2026-05-11, accepted 2026-07-04); the slowest took 567 days. The average is 220 days and the median is 208 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.